This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on april 15, 2020.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added exp date) g4 (date received by manufacturer) g7 (indication that this is a follow-up report) h2 (follow-up due to additional information and device evaluation) h3 (device evaluated by manufacturer) h4 (device manufacture date) h6 (identification of evaluation codes 10, 11, 3331, 213, 67).Method code #1: 10 - testing of actual/suspected device method code #2: 11 - testing of device from same lot/batch retained by manufacturer method code #3: 3331 - analysis of production records results code: 213 - no device problem found conclusions code: 67 - no problem detected.The actual sample was visually inspected upon receipt with no obvious anomalies, such as break in the appearance.It was then rinsed and dried, built into a circuit with tube.Bovine blood was circulated in the circuit, while the pressure drop was determined at each flow rate.The obtained valued were confirmed to meet the factory's specification and no obstruction was confirmed.After the test, a physiological saline solution was flown into the blood channel, and no blood clot that could lead to an increase in the pressure was found formed inside the sample.Review of dhr and incoming inspections results of the involved product/lot number combination confirmed there were no indications of anomalies in them.The investigation result verified that the actual sample after having been rinsed was the normal product presenting no issue relating to an increase in pressure.All available information has been placed on file in quality management for appropriate tracking, trending and follow-up.
|